Earnings Call · Q1 FY2023·2023-05-08

Q1 23EPS -29.17%·Rev n/aQ4 22EPS +4.00%·Rev n/aQ3 22EPS -42.86%·Rev n/aQ2 22EPS -16.67%·Rev n/a⚠ consensus missing

OCULAR THERAPEUTIX, INC OCUL

Donald Notman — Chief Executive Officer

Antony Mattessich — Chief Financial Officer

Rabia Ozden — Head of Clinical Development or similar clinical role

Steve Meyers — Head of Commercial or similar commercial role

+2.4%1d on move date+2.4% vs SPY3d+3.8%5d−0.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more OCUL calls or request research access.

More OCUL calls Browse calls Request research access